Gene and Cell Therapy – Products

Cellular Origins has announced the launch of Constellation, its closed, configurable, robotic platform at the International Society for Cell and Gene Therapy Annual Meeting 2023.

uBriGene, a cell & gene therapy contract development and manufacturing organization, is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc.

Waters™ Corporation has completed its acquisition of Wyatt Technology, a developer of innovative light scattering and field-flow fractionation instruments, software, accessories and services.

AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.

Lonza has launched the TheraPEAK® T-VIVO® Cell Culture Medium, a novel chemically defined medium developed to optimize CAR T-cell manufacture.

Deepcell has announced the launch of the REM-I Platform, a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model and Axon data suite.

Form Bio has announced the launch of FORMsightAI, a new, AI-based solution set for predicting and optimizing manufacturing outputs of cell and gene therapy constructs.

Waters Corp introduces its newest MaxPeak Premier Oligonucleotide Columns to support applications for nucleic acid therapeutics and cell and gene therapies.

Sino Biological provides a comprehensive range of reagents and services to support the development of CAR-T therapies targeting solid tumors.

Active cell therapy drugs represent the latest in cancer treatment. Of these, chimeric antigen receptor (CAR) cell modalities are considered the most successful.